
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc is positioned favorably due to its focus on developing innovative treatments for cancer, particularly its lead candidate, rhenium (186Re) obisbemeda, targeting high-unmet needs in central nervous system cancers. The recent constructive discussions with the FDA regarding a pivotal trial for rhenium (186Re) obisbemeda, particularly for leptomeningeal metastases, highlight a potential accelerated approval pathway, underscoring the therapy's significant clinical promise. Additionally, the successful public offering that raised approximately $15 million strengthens Plus Therapeutics's balance sheet, enhancing its operational flexibility and supporting ongoing research and development endeavors.
Bears say
The analysis indicates a negative outlook for Plus Therapeutics, primarily due to a reduced 12-month price target for the stock, which has been decreased from $2.00 to $1.00 per diluted share following a recent equity offering and the anticipated exercise of associated warrants. This adjustment reflects concerns regarding the financial impact of these developments on the company’s market valuation. Additionally, there is uncertainty surrounding the efficacy of rhenium (186Re) obisbemeda in clinical studies, as varying median overall survival rates reported in previous studies could hinder reliable comparisons and complicate future performance assessments.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares